ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The next wave of incretin therapies unveiled in New Orleans. d. 2026;4(23):46-47. Accessed July 28, 2026. https://thediabzen.com/index.php/d/article/view/66